 Antigens, Neoplasm
"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in UAMS Profiles by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 3 | 3 | | 2022 | 1 | 4 | 5 | | 2021 | 1 | 3 | 4 | | 2020 | 0 | 3 | 3 | | 2019 | 2 | 1 | 3 | | 2017 | 2 | 0 | 2 | | 2016 | 1 | 2 | 3 | | 2015 | 1 | 1 | 2 | | 2014 | 2 | 3 | 5 | | 2013 | 4 | 2 | 6 | | 2012 | 3 | 0 | 3 | | 2011 | 2 | 1 | 3 | | 2010 | 5 | 2 | 7 | | 2009 | 1 | 3 | 4 | | 2008 | 3 | 3 | 6 | | 2007 | 4 | 3 | 7 | | 2006 | 4 | 1 | 5 | | 2005 | 4 | 1 | 5 | | 2004 | 3 | 3 | 6 | | 2003 | 5 | 5 | 10 | | 2002 | 4 | 0 | 4 | | 2001 | 2 | 1 | 3 | | 2000 | 1 | 1 | 2 | | 1999 | 0 | 2 | 2 | | 1998 | 2 | 1 | 3 | | 1997 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1993 | 1 | 0 | 1 | | 1992 | 1 | 1 | 2 | | 1991 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles over the past ten years.
-
Morehead LC, Koss B, Fil D, Heflin B, Garg S, Wallis KF, Tackett AJ, Miousse IR. Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma. Mol Immunol. 2023 11; 163:188-195.
-
Guzman G, Pellot K, Reed MR, Rodriguez A. CAR T-cells to treat brain tumors. Brain Res Bull. 2023 05; 196:76-98.
-
Lauer RC, Barry M, Smith TL, Thomas AM, Wu J, Du R, Lee JH, Rao A, Dobroff AS, Arap MA, Nunes DN, Silva IT, Dias-Neto E, Chen I, McCance DJ, Cavenee WK, Pasqualini R, Arap W. Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts. Elife. 2023 01 16; 12.
-
Zengin HB, Yildiz B, Pukhalskaya T, Smoller BR. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study. J Cutan Pathol. 2023 Mar; 50(3):247-258.
-
Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Lowery FJ, Parkhurst MR, Ngo LT, Ray S, Li YF, Hill V, Florentin M, Masi RV, Paria BC, Levin N, Bera A, Hedges EA, Choi A, Chatani PD, Parikh AY, Levi S, Seitter S, Lu YC, Zheng Z, Prickett TD, Jia L, Hernandez JM, Hoang CD, Robbins PF, Goff SL, Sherry RM, Yang JC, Rosenberg SA. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunol Res. 2022 08 03; 10(8):932-946.
-
Plotzke JM, Zoumberos NA, Hrycaj SM, Harms PW, Bresler SC, Chan MP. PRAME expression is similar in scar and desmoplastic melanoma. J Cutan Pathol. 2022 09; 49(9):829-832.
-
Fatica EM, Larson BJ, Algeciras-Schimnich A, Bornhorst JA. Performance characteristics of the BRAHMS KRYPTOR automated squamous cell carcinoma antigen assay. J Immunol Methods. 2022 05; 504:113257.
-
Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ, Hill VK, Copeland AR, Nah SK, Masi RV, Gasmi B, Kivitz S, Paria BC, Florentin M, Kim SP, Hanada KI, Li YF, Ngo LT, Ray S, Shindorf ML, Levi ST, Shepherd R, Toy C, Parikh AY, Prickett TD, Kelly MC, Beyer R, Goff SL, Yang JC, Robbins PF, Rosenberg SA. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022 02 25; 375(6583):877-884.
-
Thakur S, Jain M, Zhang C, Major C, Bielamowicz KJ, Lacayo NJ, Vaske O, Lewis V, Murguia-Favela L, Narendran A. Identification and in vitro validation of neoantigens for immune activation against high-risk pediatric leukemia cells. Hum Vaccin Immunother. 2021 12 02; 17(12):5558-5562.
-
Lu YC, Zheng Z, Lowery FJ, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. J Immunother Cancer. 2021 07; 9(7).
-
Pasetto A, Lu YC. Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy. Front Immunol. 2021; 12:689091.
-
Da Vi? MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kort?m KM, Saliba AE, Rasche L. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021 04; 27(4):616-619.
-
Zhou X, Rasche L, Kort?m KM, Danhof S, Hudecek M, Einsele H. Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Front Immunol. 2020; 11:620312.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Perisetti A, Bellamkonda M, Konda M, Edwards S, Ali Khan S, Bansal P, Hu ZD, Goyal H. Tumor-associated antigens and their antibodies in the screening, diagnosis, and monitoring of esophageal cancers. Eur J Gastroenterol Hepatol. 2020 07; 32(7):779-788.
-
Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. J Immunol. 2019 06 15; 202(12):3458-3467.
-
Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger D, Malekzadeh P, Shelton TE, Prickett T, Ray S, Kivitz S, Paria BC, Kriley I, Schrump DS, Rosenberg SA. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunol Res. 2019 04; 7(4):534-543.
-
Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
-
Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Mol Ther. 2018 02 07; 26(2):379-389.
-
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329.
-
Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
-
Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. J Immunother. 2016 06; 39(5):191-201.
-
Lu YC, Robbins PF. Targeting neoantigens for cancer immunotherapy. Int Immunol. 2016 07; 28(7):365-70.
-
Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016 02; 28(1):22-7.
-
Erdem H, Gundogdu B, Ankarali H, Yasar M, Sener E, Oktay M, Bahadir A, Uzunlar AK, Gursan N, Ozaydin I, Sahiner C. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms. Niger J Clin Pract. 2015 Sep-Oct; 18(5):638-43.
-
Salama ME, Du S, Efimova O, Heikal NM, Wendlandt E, Toydemir RM, South S, Perkins SL, Hussong JW, Zhan F. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities. Leuk Lymphoma. 2015 Feb; 56(2):426-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|